Strategies for Preclinical Studies Evaluating the Biological Effects of an Accelerator-based BNCT System

This review discusses the strategies of preclinical studies intended for accelerator-based (AB)-boron neutron capture therapy (BNCT) clinical trials, which were presented at the National Cancer Institute (NCI) Workshop on Neutron Capture Therapy held from April 20 to 22, 2022. Clinical studies of BNCT have been conducted worldwide using reactor neutron sources, with most targeting malignant brain tumors, melanoma, or head and neck cancer. Recently, small accelerator-based neutron sources that can be installed in hospitals have been developed. AB-BNCT clinical trials for recurrent malignant glioma, head and neck cancers, high-grade meningioma, melanoma, and angiosarcoma have all been conducted in Japan. The necessary methods, equipment, and facilities for preclinical studies to evaluate the biological effects of AB-BNCT systems in terms of safety and efficacy are described, with reference to two examples from Japan. The first is the National Cancer Center, which is equipped with a vertical downward neutron beam, and the other is the University of Tsukuba, which has a horizontal neutron beam. The preclinical studies discussed include cell-based assays to evaluate cytotoxicity and genotoxicity, in vivo cytotoxicity and efficacy of BNCT, and radioactivation measurements

Melanic mutation causes a fitness decline in bean beetles infected by Wolbachia

Wolbachia cannot live outside a host, which is thought to be the reason for host‐Wolbachia coevolution toward benign parasitism, especially because the fitness of Wolbachia is traded against its host\u27s fitness. Insect melanism has been reported to have a positive effect on pathogen resistance, but melanic mutants of Callosobruchus analis (Fabricius) and Callosobruchus chinensis (L.) (Coleoptera: Chrysomelidae) are infected with Wolbachia. Callosobruchus chinensis is infected with CI‐inducing Wolbachia, and melanic mutants exhibit fitness decline. Interestingly, this decline is not observed in C. analis melanic mutants that are infected with CI‐free Wolbachia. Our research question is whether the infection of CI‐inducing Wolbachia causes fitness decline of melanic hosts in C. analis. We examined fecundity, fertility, and longevity of C. analis melanic mutants and compared them between uninfected and infected hosts with CI‐inducing Wolbachia. Infected melanic mutants of C. analis exhibited fitness decline leading to reduced hatch rates even when parental combinations were compatible. Wolbachia can invade a host population by causing CI to decrease the fraction of uninfected hosts, but melanic mutant hosts decrease the number of infected hosts through fitness decline. Nevertheless, the melanism in hosts is not able to stop Wolbachia invasion in C. analis

DNA Barcoding, Environmental DNA and an Ongoing Attempt of Detecting Biodiversity in Lake Kasumigaura

Symposium Pape

NADPH oxidase and ROS in kidney growth

Ureteric bud branching and nephrogenesis are performed through large-scale proliferation and apoptosis events during renal development. Reactive oxygen species (ROS), produced by NADPH oxidase, may contribute to cell behaviors, including proliferation and apoptosis. We investigated the role of NADPH oxidase expression and ROS production in developing kidneys. Immunohistochemistry revealed that NADPH oxidase components were expressed on epithelial cells in ureteric bud branches, as well as on immature glomerular cells and epithelial cells in nephrogenic zones. ROS production, detected by dihydroethidium assay, was strongly observed in ureteric bud branches and nephrogenic zones, corresponding with NADPH oxidase localization. Organ culture of E14 kidneys revealed that the inhibition of NADPH oxidase significantly reduced the number of ureteric bud branches and tips, consistent with reduced ROS production. This was associated with reduced expression of phosphorylated ERK1/2 and increased expression of cleaved caspase-3. Organ culture of E18 kidneys showed that the inhibition of NADPH oxidase reduced nephrogenic zone size, accompanied by reduced ROS production, fewer proliferating cell nuclear antigen-positive cells, lower p-ERK1/2 expression, and increased expression of cleaved caspase-3. These results demonstrate that ROS produced by NADPH oxidase might play an important role in ureteric bud branching and nephrogenesis by regulating proliferation and apoptosis

Self-assembling A6K peptide nanotubes as a mercaptoundecahydrododecaborate (BSH) delivery system for boron neutron capture t (BNCT)

Boron neutron capture therapy (BNCT) is a tumor selective therapy, the effectiveness of which depends on sufficient 10B delivery to and accumulation in tumors. In this study, we used self-assembling A6K peptide nanotubes as boron carriers and prepared new boron agents by simple mixing of A6K and BSH. BSH has been used to treat malignant glioma patients in clinical trials and its drug safety and availability have been confirmed; however, its contribution to BNCT efficacy is low. A6K nanotube delivery improved two major limitations of BSH, including absence of intracellular transduction and non-specific drug delivery to tumor tissue. Varying the A6K peptide and BSH mixture ratio produced materials with different morphologies—determined by electron microscopy—and intracellular transduction efficiencies. We investigated the A6K/BSH 1:10 mixture ratio and found high intracellular boron uptake with no toxicity. Microscopy observation showed intracellular localization of A6K/BSH in the perinuclear region and endosome in human glioma cells. The intracellular boron concentration using A6K/BSH was almost 10 times higher than that of BSH. The systematic administration of A6K/BSH via mouse tail vein showed tumor specific accumulation in a mouse brain tumor model with immunohistochemistry and pharmacokinetic study. Neutron irradiation of glioma cells treated with A6K/BSH showed the inhibition of cell proliferation in a colony formation assay. Boron delivery using A6K peptide provides a unique and simple strategy for next generation BNCT drugs

Development of a dual phantom technique for measuring the fast neutron component of dose in boron neutron capture therapy.

[Purpose]: Research and development of various accelerator-based irradiation systems for boron neutroncapture therapy (BNCT) is underway throughout the world. Many of these systems are nearing or have started clinical trials. Before the start of treatment with BNCT, the relative biological effectiveness (RBE) for the fast neutrons (over 10 keV) incident to the irradiation field must be estimated. Measurements of RBE are typically performed by biological experiments with a phantom. Although the dose deposition due to secondary gamma rays is dominant, the relative contributions of thermal neutrons (below 0.5 eV) and fast neutrons are virtually equivalent under typical irradiationconditions in a water and/or acrylic phantom. Uniform contributions to the dose deposited from thermal and fast neutrons are based in part on relatively inaccurate dose information for fastneutrons. This study sought to improve the accuracy in the dose estimation for fast neutrons by using two phantoms made of different materials in which the dose components can be separated according to differences in the interaction cross sections. The development of a “dual phantom technique” for measuring the fast neutron component of dose is reported. [Methods]: One phantom was filled with pure water. The other phantom was filled with a water solution of lithiumhydroxide (LiOH) capitalizing on the absorbing characteristics of lithium-6 (Li-6) for thermal neutrons.Monte Carlo simulations were used to determine the ideal mixing ratio of Li-6 in LiOH solution.Changes in the depth dose distributions for each respective dose component along the central beam axis were used to assess the LiOH concentration at the 0, 0.001, 0.01, 0.1, 1, and 10 wt. % levels. Simulations were also performed with the phantom filled with 10 wt. % [6]LiOH solution for 95%-enriched Li-6. A phantom was constructed containing 10 wt. % [6]LiOH solution based on the simulation results. Experimental characterization of the depth dose distributions of the neutron andgamma-ray components along the central axis was performed at Heavy Water Neutron IrradiationFacility installed at Kyoto University Reactor using activation foils and thermoluminescent dosimeters, respectively. [Results]: Simulation results demonstrated that the absorbing effect for thermal neutrons occurred when the LiOH concentration was over 1%. The most effective Li-6 concentration was determined to be enriched [6]LiOH with a solubility approaching its upper limit. Experiments confirmed that the thermalneutron flux and secondary gamma-ray dose rate decreased substantially; however, the fastneutron flux and primary gamma-ray dose rate were hardly affected in the 10%-[6]LiOH phantom. It was confirmed that the dose contribution of fast neutrons is improved from approximately 10% in the pure water phantom to approximately 50% in the 10%-[6]LiOH phantom. [Conclusions]: The dual phantom technique using the combination of a pure water phantom and a 10%-[6]LiOH phantom developed in this work provides an effective method for dose estimation of the fast neutroncomponent in BNCT. Improvement in the accuracy achieved with the proposed technique results in improved RBE estimation for biological experiments and clinical practice